Document is current
Any future updates will be listed below
-
Authors
Arriens, Cristina https://orcid.org/0000-0002-9546-1664
Morand, Eric F. https://orcid.org/0000-0002-9507-3338
Askanase, Anca D. https://orcid.org/0000-0003-4597-5023
Furie, Richard https://orcid.org/0000-0001-6712-1585
van Vollenhoven, Ronald F. https://orcid.org/0000-0001-6438-8663
Tanaka, Yoshiya https://orcid.org/0000-0002-0807-7139
Connors, Kevin https://orcid.org/0009-0007-2096-7023
Davey, Monica https://orcid.org/0009-0007-0314-5693
Young, Kimberly https://orcid.org/0009-0003-5930-2767
Franchin, Giovanni https://orcid.org/0000-0003-2609-7974
Meier, Richard
Shah, Vaishali https://orcid.org/0009-0009-9321-9338
de Oliveria, Carolina Leite https://orcid.org/0000-0003-4860-7509
Hobar, Coburn https://orcid.org/0009-0006-5935-7997
-
Funding
Funding for this research was provided by:
Bristol-Myers Squibb
- License Information
-
More Information
Article History
Received: 19 March 2025
Accepted: 27 June 2025
First Online: 8 September 2025
Declarations
:
: Cristina Arriens received grants, advisory fees, and/or speaker honoraria from AstraZeneca, Aurinia, Bristol Myers Squibb, Cabaletta, GSK, Health & Wellness Partners, Kezar, Synthekine, and UCB. Eric F. Morand received consulting fees and/or research support from AbbVie, Amgen, AstraZeneca, Biogen, Bristol Myers Squibb, Dragonfly, Eli Lilly, EMD Serono, Genentech, Gilead, GSK, Janssen, Novartis, RemeGen, Takeda, UCB, and Zenas. Anca D. Askanase received investigator and consultancy fees from AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Celgene, Eli Lilly, Genentech, GSK, Idorsia, Janssen, Pfizer, and UCB. Richard Furie received grant support and consulting fees from Bristol Myers Squibb. Ronald F. van Vollenhoven received research support, educational program support, consultancy, and/or speaker fees from AbbVie, AstraZeneca, Biogen, Biotest, Bristol Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead, GSK, Janssen, Pfizer, Roche, Servier, and UCB. Yoshiya Tanaka received research grants, speaking fees, and/or honoraria from AbbVie, Eisai, Chugai, Eli Lilly, Boehringer Ingelheim, GSK, Taisho, AstraZeneca, Daiichi Sankyo, Gilead, Pfizer, UCB, Asahi Kasei, and Astellas. Kevin Connors, Monica Davey, Kimberly Young, Richard Meier, Vaishali Shah, and Carolina Leite de Oliveira are employees and shareholders of Bristol Myers Squibb. Giovanni Franchin was an employee and shareholder of Bristol Myers Squibb at the time of manuscript development and is currently an employee of Novartis Pharmaceuticals Corporation. Coburn Hobar was an employee and shareholder of Bristol Myers Squibb at the time of manuscript development. The funding sponsors were involved in the choice of research project; the design of the study; the collection, analyses, and interpretation of data; the writing of the manuscript; and in the decision to publish the results.
: All patients must provide informed consent, and the protocols (code IM011246 and IM011247 on August 12, 2022) must receive approval from the IRB/IEC associated with each site. Investigators must have IRB/IEC approval of informed consent forms and other study documents as required, obtain a signed and dated consent form, and revise the consent form if any new information that is relevant to participation arises. Both studies will be conducted in accordance with international guidelines, including the Declaration of Helsinki and Council for International Organizations of Medical Sciences and applicable International Council for Harmonisation Good Clinical Practice guidelines.
